Abstract
Stem cell therapy has an unparalleled potential to treat blood cancers, cardiovascular diseases and neurodegenerative conditions, among others. However, stem cell therapeutics must overcome multiple requirements before reaching clinical trials, including large animal safety and efficacy studies. In cardiovascular diseases swine models are the most widely adopted due to its great translational potential to humans. In this chapter, we will describe several protocols to induce iPSC dedifferentiation in swine fibroblasts, as well as conditioning treatments that may help in the reprogramming process.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663–676
Tsang HG, Rashdan NA, Whitelaw CBA et al (2016) Large animal models of cardiovascular disease. Cell Biochem Funct 34:113–132
Wu Z, Chen J, Ren J et al (2009) Generation of pig induced pluripotent stem cells with a drug-inducible system. J Mol Cell Biol 1:46–54
Du X, Feng T, Yu D et al (2015) Barriers for deriving transgene-free pig iPS cells with episomal vectors. Stem Cells 33:3228–3238
Wang G, Weng R, Lan Y et al (2017) Synergetic effects of DNA methylation and histone modification during mouse induced pluripotent stem cell generation. Sci Rep 7:39527
Tarkowski A (1966) An air-drying method for chromosome preparations from mouse eggs. Cytogenet Genome Res 5:394–400
Acknowledgments
This work was supported by Fundació La Marató de TV3 (201516-10, 201502-30), Generalitat de Catalunya (Departament de Salut) PERIS Acció Instrumental de Programes de Recerca Orientats (SLT002/16/00234 and SLT002/16/00209) and AGAUR (2017-SGR-483), “La Caixa” Banking Foundation, grants from the Spanish Ministry of Economy and Competitiveness-MINECO (SAF2017-84324-C2-1-R and PID2019-110137RB-I00), Institute of Health Carlos III (ISCIII) [PI18/00256, PIC18/00014, ICI19/00039, PI19/01788, and ICI20/00135], and cofunded by European Union (ERDF/ESF)—A way to build Europe. This work has also been funded by the Sociedad Española de Cardiología and by the Call for Expression of Interest (EoI) for Collaborative Projects on Regenerative Medicine 2019 of Centre for Regenerative Medicine of Barcelona (CMR[B]), Red de Terapia Celular-TerCel (RD16/00111/0006 and RD16/0011/0024), and CIBER Cardiovascular (CB16/11/00403) projects, as a part of the Plan Nacional de I + D + I, and it was cofunded by ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Iborra-Egea, O., Martínez-Falguera, D., Roura, S., Bayes-Genis, A., Raya, Á., Gálvez-Montón, C. (2021). Porcine iPSC Generation: Testing Different Protocols to a Successful Application. In: Nagy, A., Turksen, K. (eds) Induced Pluripotent Stem (iPS) Cells. Methods in Molecular Biology, vol 2454. Humana, New York, NY. https://doi.org/10.1007/7651_2021_446
Download citation
DOI: https://doi.org/10.1007/7651_2021_446
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-2118-9
Online ISBN: 978-1-0716-2119-6
eBook Packages: Springer Protocols